Please enable JavaScript to continue using this application.

Compare $SYRE vs $TGTX | Chartloom

Compare

$SYRE vs $TGTX

Spyre Therapeutics Inc · TG Therapeutics Inc

SYRE

Spyre Therapeutics Inc

TGTX

TG Therapeutics Inc

Compare $SYRE vs $TGTX

Comparing Spyre Therapeutics Inc and TG Therapeutics Inc

SYRESpyre Therapeutics Inc

TGTXTG Therapeutics Inc

SYRESpyre Therapeutics Inc

Market cap

$7.44B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

180.2%

52W performance

384.7%

FCF yield

-2.8%

TGTXTG Therapeutics Inc

Market cap

$8.48B

P/E (TTM)

19.73x

Forward P/E (NTM)

28.29x

Forward P/S (NTM)

7.51x

Rev growth (TTM)

76.1%

YTD performance

89.1%

52W performance

54.9%

FCF yield

0.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

SYRE

TGTX

Detailed metrics comparison

SYRE

Spyre Therapeutics Inc

TGTX

TG Therapeutics Inc

Market Cap

SYRE$7.44B

TGTX$8.48B

Enterprise Value

SYRE$7.28B

TGTX$8.74B

Price

SYRE$85.69

TGTX$55.37

P/E Ratio

SYREN/A

TGTX19.73x

P/S Ratio

SYRE6,680.42x

TGTX10.60x

EV/Sales

SYRE0.00x

TGTX10.93x

EV/EBITDA

SYRE0.00x

TGTX63.06x

P/B Ratio

SYRE7.46x

TGTX13.76x

P/FCF Ratio

SYREN/A

TGTX487.55x

EV/FCF

SYRE-34.84x

TGTX502.67x

PEG Ratio

SYREN/A

TGTX0.83x

Forward P/E (NTM)

SYREN/A

TGTX28.29x

Forward P/S (NTM)

SYREN/A

TGTX7.51x

Revenue (TTM)

SYRE$0

TGTX$800M

Revenue Growth (YoY)

SYREN/A

TGTX76.1%

Forward Rev Growth

SYRE231.1%

TGTX35.6%

Gross Margin (TTM)

SYRE0.0%

TGTX82.4%

Operating Margin (TTM)

SYRE0.0%

TGTX15.9%

EBITDA Margin (TTM)

SYRE0.0%

TGTX17.1%

Net Margin (TTM)

SYRE0.0%

TGTX55.2%

FCF Margin (TTM)

SYREN/A

TGTX2.2%

Net Income (TTM)

SYRE$-179M

TGTX$441M

FCF (TTM)

SYRE$-209M

TGTX$17M

EPS (TTM)

SYRE-$2.11

TGTX$2.81

ROE (TTM)

SYRE-2432.0%

TGTX72.3%

ROA (TTM)

SYRE-2223.0%

TGTX33.6%

ROIC (TTM)

SYRE-2432.0%

TGTX39.9%

Cash

SYRE$162M

TGTX$483M

Debt

SYRE$0

TGTX$745M

Net Cash/Debt

SYRE$162M

TGTX$-263M

Current Ratio (TTM)

SYRE18.53x

TGTX4.27x

Quick Ratio (TTM)

SYRE18.09x

TGTX3.72x

Debt/Equity (TTM)

SYRE0.00x

TGTX1.23x

Debt/Assets (TTM)

SYRE0.0%

TGTX0.0%

Interest Coverage (TTM)

SYREN/A

TGTXN/A

Net Debt/EBITDA (TTM)

SYRE0.00x

TGTX0.00x

Beta

SYRE3.19

TGTX1.82

52W Performance

SYRE384.7%

TGTX54.9%

YTD Performance

SYRE180.2%

TGTX89.1%

% from 52W High

SYRE-22.2%

TGTX-6.6%

% from 52W Low

SYRE385.5%

TGTX106.9%

Asset Turnover (TTM)

SYRE0.01x

TGTX0.61x

FCF Yield (TTM)

SYRE-2.8%

TGTX0.2%

Earnings Yield (TTM)

SYRE-2.4%

TGTX5.2%

Dividend Yield (TTM)

SYREN/A

TGTXN/A

Rule of 40

SYRE0.0

TGTX78.3

EV/GP/RG

SYREN/A

TGTX0.32

Ticker research

View SYRE research View TGTX research

Metric	SYRE Spyre Therapeutics Inc	TGTX TG Therapeutics Inc
Market & Valuation
Market Cap	$7.44B	$8.48B
Enterprise Value	$7.28B	$8.74B
Price	$85.69	$55.37
P/E Ratio	N/A	19.73x
P/S Ratio	6,680.42x	10.60x
EV/Sales	0.00x	10.93x
EV/EBITDA	0.00x	63.06x
P/B Ratio	7.46x	13.76x
P/FCF Ratio	N/A	487.55x
EV/FCF	-34.84x	502.67x
PEG Ratio	N/A	0.83x
Forward P/E (NTM)	N/A	28.29x
Forward P/S (NTM)	N/A	7.51x
Revenue & Growth
Revenue (TTM)	$0	$800M
Revenue Growth (YoY)	N/A	76.1%
Forward Rev Growth	231.1%	35.6%
Profitability
Gross Margin (TTM)	0.0%	82.4%
Operating Margin (TTM)	0.0%	15.9%
EBITDA Margin (TTM)	0.0%	17.1%
Net Margin (TTM)	0.0%	55.2%
FCF Margin (TTM)	N/A	2.2%
Net Income (TTM)	$-179M	$441M
FCF (TTM)	$-209M	$17M
EPS (TTM)	-$2.11	$2.81
ROE (TTM)	-2432.0%	72.3%
ROA (TTM)	-2223.0%	33.6%
ROIC (TTM)	-2432.0%	39.9%
Financial Health
Cash	$162M	$483M
Debt	$0	$745M
Net Cash/Debt	$162M	$-263M
Current Ratio (TTM)	18.53x	4.27x
Quick Ratio (TTM)	18.09x	3.72x
Debt/Equity (TTM)	0.00x	1.23x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.19	1.82
52W Performance	384.7%	54.9%
YTD Performance	180.2%	89.1%
% from 52W High	-22.2%	-6.6%
% from 52W Low	385.5%	106.9%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.61x
FCF Yield (TTM)	-2.8%	0.2%
Earnings Yield (TTM)	-2.4%	5.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	78.3
EV/GP/RG	N/A	0.32
Ticker research	View SYRE research	View TGTX research

Valuation

P/E Ratio

TGTX

19.73x

P/S Ratio

TGTX

10.60x

SYRE

6,680.42x

EV/FCF

SYRE

-34.84x

TGTX

502.67x

Growth & revenue

Revenue Growth TTM

TGTX

76.1%

Forward Revenue Growth

SYRE

231.1%

TGTX

35.6%

Profitability & performance

Gross Margin

TGTX

82.4%

SYRE

0.0%

ROE

TGTX

72.3%

SYRE

-2432.0%

FCF Yield %

TGTX

0.2%

SYRE

-2.8%

52-Week Performance

SYRE

384.7%

TGTX

54.9%

Detailed metrics comparison

SYRE

Spyre Therapeutics Inc

TGTX

TG Therapeutics Inc

Market Cap

SYRE$7.44B

TGTX$8.48B

Enterprise Value

SYRE$7.28B

TGTX$8.74B

Price

SYRE$85.69

TGTX$55.37

P/E Ratio

SYREN/A

TGTX19.73x

P/S Ratio

SYRE6,680.42x

TGTX10.60x

EV/Sales

SYRE0.00x

TGTX10.93x

EV/EBITDA

SYRE0.00x

TGTX63.06x

P/B Ratio

SYRE7.46x

TGTX13.76x

P/FCF Ratio

SYREN/A

TGTX487.55x

EV/FCF

SYRE-34.84x

TGTX502.67x

PEG Ratio

SYREN/A

TGTX0.83x

Forward P/E (NTM)

SYREN/A

TGTX28.29x

Forward P/S (NTM)

SYREN/A

TGTX7.51x

Revenue (TTM)

SYRE$0

TGTX$800M

Revenue Growth (YoY)

SYREN/A

TGTX76.1%

Forward Rev Growth

SYRE231.1%

TGTX35.6%

Gross Margin (TTM)

SYRE0.0%

TGTX82.4%

Operating Margin (TTM)

SYRE0.0%

TGTX15.9%

EBITDA Margin (TTM)

SYRE0.0%

TGTX17.1%

Net Margin (TTM)

SYRE0.0%

TGTX55.2%

FCF Margin (TTM)

SYREN/A

TGTX2.2%

Net Income (TTM)

SYRE$-179M

TGTX$441M

FCF (TTM)

SYRE$-209M

TGTX$17M

EPS (TTM)

SYRE-$2.11

TGTX$2.81

ROE (TTM)

SYRE-2432.0%

TGTX72.3%

ROA (TTM)

SYRE-2223.0%

TGTX33.6%

ROIC (TTM)

SYRE-2432.0%

TGTX39.9%

Cash

SYRE$162M

TGTX$483M

Debt

SYRE$0

TGTX$745M

Net Cash/Debt

SYRE$162M

TGTX$-263M

Current Ratio (TTM)

SYRE18.53x

TGTX4.27x

Quick Ratio (TTM)

SYRE18.09x

TGTX3.72x

Debt/Equity (TTM)

SYRE0.00x

TGTX1.23x

Debt/Assets (TTM)

SYRE0.0%

TGTX0.0%

Interest Coverage (TTM)

SYREN/A

TGTXN/A

Net Debt/EBITDA (TTM)

SYRE0.00x

TGTX0.00x

Beta

SYRE3.19

TGTX1.82

52W Performance

SYRE384.7%

TGTX54.9%

YTD Performance

SYRE180.2%

TGTX89.1%

% from 52W High

SYRE-22.2%

TGTX-6.6%

% from 52W Low

SYRE385.5%

TGTX106.9%

Asset Turnover (TTM)

SYRE0.01x

TGTX0.61x

FCF Yield (TTM)

SYRE-2.8%

TGTX0.2%

Earnings Yield (TTM)

SYRE-2.4%

TGTX5.2%

Dividend Yield (TTM)

SYREN/A

TGTXN/A

Rule of 40

SYRE0.0

TGTX78.3

EV/GP/RG

SYREN/A

TGTX0.32

Ticker research

View SYRE research View TGTX research

Metric	SYRE Spyre Therapeutics Inc	TGTX TG Therapeutics Inc
Market & Valuation
Market Cap	$7.44B	$8.48B
Enterprise Value	$7.28B	$8.74B
Price	$85.69	$55.37
P/E Ratio	N/A	19.73x
P/S Ratio	6,680.42x	10.60x
EV/Sales	0.00x	10.93x
EV/EBITDA	0.00x	63.06x
P/B Ratio	7.46x	13.76x
P/FCF Ratio	N/A	487.55x
EV/FCF	-34.84x	502.67x
PEG Ratio	N/A	0.83x
Forward P/E (NTM)	N/A	28.29x
Forward P/S (NTM)	N/A	7.51x
Revenue & Growth
Revenue (TTM)	$0	$800M
Revenue Growth (YoY)	N/A	76.1%
Forward Rev Growth	231.1%	35.6%
Profitability
Gross Margin (TTM)	0.0%	82.4%
Operating Margin (TTM)	0.0%	15.9%
EBITDA Margin (TTM)	0.0%	17.1%
Net Margin (TTM)	0.0%	55.2%
FCF Margin (TTM)	N/A	2.2%
Net Income (TTM)	$-179M	$441M
FCF (TTM)	$-209M	$17M
EPS (TTM)	-$2.11	$2.81
ROE (TTM)	-2432.0%	72.3%
ROA (TTM)	-2223.0%	33.6%
ROIC (TTM)	-2432.0%	39.9%
Financial Health
Cash	$162M	$483M
Debt	$0	$745M
Net Cash/Debt	$162M	$-263M
Current Ratio (TTM)	18.53x	4.27x
Quick Ratio (TTM)	18.09x	3.72x
Debt/Equity (TTM)	0.00x	1.23x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.19	1.82
52W Performance	384.7%	54.9%
YTD Performance	180.2%	89.1%
% from 52W High	-22.2%	-6.6%
% from 52W Low	385.5%	106.9%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.61x
FCF Yield (TTM)	-2.8%	0.2%
Earnings Yield (TTM)	-2.4%	5.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	78.3
EV/GP/RG	N/A	0.32
Ticker research	View SYRE research	View TGTX research